AstraZeneca Results Presentation Deck

100% 50% BioPharmaceuticals - 9M and Q3 2023 Portfolio evolution enables long-term sustainable growth 0% Key R&I medicines grew 42% in Q3 2023 % of R&I Total Revenue Q3 2020 ■ Fasenra ■ Breztri !! Q3 2021 Q3 2022 Q3 2023 +42% growth in Q3 Tezspire Symbicort Daliresp ■ Saphnelo ■ Pulmicort ■ Other CEO Opening Remarks Growth of newer brands more than offset generic impact on older medicines Financial Results Tezspire market leadership within first year of launch New-to-brand share¹ in severe uncontrolled asthma Germany Oncology Tezspire Nearest competitor Others BioPharmaceuticals Tezspire market share expansion globally within growing class 60% OLL Japan 40% 100% Farxiga - substantial growth opportunity remains 80% 20% 0% Rare Disease Potential to increase proportion of diagnosed and treated CKD and HF patients 26% CEO Closing Remarks CKD 17% 66% I 17% HF Prevalent Diagnosed Treated to guideline Farxiga growth strengthens foundation for next-gen CVRM 1. Based on internal new to brand prescription (NBRx) analysis by AstraZeneca UK Limited using data from the following sources: IQVIA Japan Rx, and IQVIA Germany LRX, IQVIA PharmaScope® National and IQVIA DKMⓇ data for the period Aug 2023, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved. 2. Sources for CKD & HF prevalence: 1Jager KJ, et al; Nephrol Dial Transplant. 2019;34(11):1803-1805. 2Vos T et al. The Lancet. 2017; 390(10100):1211-59. Analysis prepared based on: Germany, France, Italy, Spain, UK and US using AZ internal projections provided by local marketing companies. CKD prevalence and diagnosis based on Stages 2b-4a; treated to guideline is based on total SGLT2i penetration July 2023 IQVIA EMR patient record data US, EU3 and UK; Telomera patient record data for Spain. R&I = respiratory and immunology; LoE = loss of exclusivity; CKD = chronic kidney disease; CVRM = Cardiovascular, Renal and Metabolism; LCM = lifecycle management. Collaboration partners: Amgen (Tezspire). 23

View entire presentation